• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Takeda, Stanford University announce alliance

Takeda, Stanford University announce alliance

August 17, 2017
CenterWatch Staff

Takeda Pharmaceutical has announced a collaboration with Stanford University to form the Stanford Alliance for Innovative Medicines (Stanford AIM), which will help transform novel Stanford research into next-generation treatments for diseases. Through this unique collaboration, Takeda and Stanford will identify projects on the path to therapeutic discoveries and accelerate the process of bringing these drugs to market to serve patients with unmet needs.

Stanford AIM will leverage the collective knowledge and experience of Stanford and Takeda scientists in order to propel health discoveries through therapeutic development. By encouraging academic and industry scientists to work more closely together, the partnership aims to expedite promising new medicines that represent real and meaningful benefits for patients.

“Takeda’s alliance with Stanford demonstrates our commitment to advancing medicines as quickly and efficiently as possible—from drug discovery to development and ultimately to patients,” said Juan Harrison, Vice President, Head of Strategic Academic Alliances, Center for External Innovation, Takeda. “We look forward to combining the intellectual capital of Takeda and Stanford scientists, motivating both to come together as peers, in order to deliver medicines that represent real and meaningful benefits for patients.”

The partners expect to begin taking proposals from Stanford lab teams in October, which will include objectives against which to measure progress and success during key phases of research. Together, Takeda and Stanford will identify the most promising novel, innovative projects. Upon project selection, Takeda will apply its best-in-class capabilities—including scientific and clinical research and operations—to develop the pathway or platform technology.

This type of collaboration advances the validation of projects born at Stanford and improves the potential for discoveries to be developed and licensed, while exposing Takeda researchers to the latest biological discoveries and innovative chemical platforms from a leading research university. The three-year term of the collaboration will support four to eight projects running concurrently at a given time.

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing